EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Reversible Cerebral Vasoconstriction Syndrome Secondary to Dermatologic Cream: A Case Report

Mark Edward Wilhelm, Andrew Joseph Sessions, Gitanjali Das, Benson H Sederholm, Jennifer Juhl Majersik

Case Reports in Neurology · 26.08.2026 · 18 (1) · 594-599

DOI: 10.1159/crn/abyag007 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Neurology, online erschienen am 26.08.2026. Verfasst von Mark Edward Wilhelm und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, School of Medicine, University of Utah, Salt Lake City, UT, USA. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Imiquimod is an FDA-approved prescription topical medication used in the treatment of skin lesions and neoplasms, such as actinic keratosis, superficial basal cell carcinoma, and external genital and perianal warts. The etiology of rare CNS effects, including headache and stroke, is not completely understood. Headache is a commonly reported adverse reaction, while stroke has been identified through postmarketing pharmacovigilance reports without a definitively established causal relationship. Case Presentation: A 60-year-old female with mild depression and basal cell carcinoma, and an absence of traditional vascular risk factors, presented with a 2-week history of new recurrent thunderclap headaches. CT angiogram showed 40–50% narrowing of the proximal right A1. Conventional angiography demonstrated multiple regions of vasoconstriction which improved with intra-arterial verapamil, supporting the diagnosis of reversible cerebral vasoconstrictive syndrome (RCVS) diagnosis. Oral verapamil was up-titrated to 40 mg every 3 h for vasospasm and headache control. At 4-week follow-up, there was only residual A1 stenosis. Pre-RCVS, the patient had been diagnosed with basal cell carcinoma and was prescribed imiquimod 5% cream, with instructions to apply one 0.25-g prefilled packet topically once daily, which she used for 8.5 weeks prior to symptom onset. The patient had been on a stable low dose (2.5 mg daily) of escitalopram, a selective serotonin reuptake inhibitor and recognized potential trigger of RCVS, for several years without prior neurological symptoms. Discontinuation after the first headache did not prevent subsequent episodes, making it less likely to be the sole precipitant, though a contributory role cannot be excluded. In the absence of other vasoactive substances or identifiable etiologies for vasculitis, we suspect that topical imiquimod was responsible for RCVS in this case.

Conclusion

Imiquimod is an immune modulating agent that acts as a toll-like receptor (TLR) 7 agonist, causing cytokine induction, inflammatory infiltration, and tumor cell apoptosis. Though headache and stroke are reported as rare side effects, stroke subtype and etiology are uncharacterized, with no RCVS reported to our knowledge. A moyamoya animal model, a pathophysiologically distinct entity from RCVS, demonstrated that using imiquimod to induce TLR-7 activation resulted in a phenotypic change in vascular smooth muscle cells. In vivo, imiquimod also led to diminished internal carotid artery blood flow, while inhibiting TLR-7 resulted in decreased stenosis. These findings suggest that imiquimod-mediated TLR-7 agonism can directly alter cerebrovascular smooth muscle behavior – a mechanism that is biologically plausible as a contributor to the acute vasospasm observed in RCVS. Topical imiquimod is thought to trigger systemic reactions secondary to increased production and circulation of cytokines originating from dermal absorption. Further studies are warranted to evaluate the risk of topical imiquimod use as it relates to cerebral vascular emergencies. We recommend that clinicians consider systemic effects of topical medications as potential contributors to neurologic sequelae.

Schlagwörter

Stichwörter der Autor:innen

Adverse effectCase reportCentral nervous systemImiquimodReversible cerebral vasoconstriction syndromeTopical medication

Autor:innen und Institutionen

  • Department of Neurology, School of Medicine, University of Utah, Salt Lake City, UT, USA.
  • School of Medicine, University of Utah, Salt Lake City, UT, USA.
  • Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
  • Department of Pharmacy Services, University of Utah Health, Salt Lake City, UT, USA.

Zitieren

APA

Wilhelm, M. E., Sessions, A. J., Das, G., Sederholm, B. H., & Majersik, J. J. (2026). Reversible Cerebral Vasoconstriction Syndrome Secondary to Dermatologic Cream: A Case Report. Case Reports in Neurology, 18(1), 594-599. https://doi.org/10.1159/crn/abyag007

Vancouver

Wilhelm ME, Sessions AJ, Das G, Sederholm BH, Majersik JJ. Reversible Cerebral Vasoconstriction Syndrome Secondary to Dermatologic Cream: A Case Report. Case Reports in Neurology. 2026;18(1):594-599. doi:10.1159/crn/abyag007

BibTeX
@article{Wilhelm2026,
  author = {Wilhelm, Mark Edward and Sessions, Andrew Joseph and Das, Gitanjali and Sederholm, Benson H and Majersik, Jennifer Juhl},
  title = {Reversible Cerebral Vasoconstriction Syndrome Secondary to Dermatologic Cream: A Case Report},
  journal = {Case Reports in Neurology},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {594--599},
  doi = {10.1159/crn/abyag007}
}
Kostenlos starten →